A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: Paget's Disease of Bone

Treatments: Drug: alendronate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00480662

MK0217-206

0217-206

2007_555

Details and patient eligibility

About

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Enrollment: 60 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease

Exclusion criteria

• Patient cannot stand or sit upright for at least 30 minutes
• Patient has difficulty swallowing or problems with digestive system

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind